On World Population Day, we reflect on the critical importance of addressing the health needs of our growing global population. With over 8 billion people on our planet, the challenge to provide equitable healthcare is greater than ever. At CureVac, we are dedicated to leveraging cutting-edge mRNA technology to develop innovative vaccines and therapeutics to advance human health. The idea of a healthier future for all people across the world is something that guides us every day in our work. We’re proud to be part of a larger ecosystem of innovators breaking through to new frontiers in medicine that will get us closer to this vision. Learn more about World Population Day: https://lnkd.in/dFFePXn #WorldPopulationDay #CureVac #HealthcareInnovation #SustainableDevelopment #mRNATechnology #GlobalHealth
CureVac
Biotechnologieforschung
Tübingen, Baden-Württemberg 50.843 Follower:innen
We fight for human health - we are the RNA people
Info
CureVac (Nasdaq: CVAC) is a global biopharmaceutical company in the field of messenger RNA (mRNA) technology, with more than 20 years of expertise in developing, optimizing, and manufacturing this versatile biological molecule for medical purposes. The principle of CureVac’s proprietary technology is the use of optimized mRNA as a data carrier to instruct the human body to produce its own proteins capable of fighting a broad range of diseases. In July 2020, CureVac entered in a collaboration with GSK to jointly develop new products in prophylactic vaccines for infectious diseases based on CureVac’s second-generation mRNA technology. This collaboration was later extended to the development of second-generation COVID-19 vaccine candidates, and modified mRNA vaccine technologies. Based on its proprietary technology, CureVac has built a deep clinical pipeline across the areas of prophylactic vaccines, cancer therapies, antibody therapies, and the treatment of rare diseases. CureVac N.V. has its headquarters in Tübingen, Germany, and has more than 1,100 employees across its sites in Germany, the Netherlands, Belgium, Switzerland and the U.S. Further information can be found at www.curevac.com.
- Website
-
http://curevac.com
Externer Link zu CureVac
- Branche
- Biotechnologieforschung
- Größe
- 1.001–5.000 Beschäftigte
- Hauptsitz
- Tübingen, Baden-Württemberg
- Art
- Kapitalgesellschaft (AG, GmbH, UG etc.)
- Gegründet
- 2000
- Spezialgebiete
- mRNA therapeutics, cancer therapies, prophylactic vaccines, molecular therapies, oncology, research and development und manufacturing
Orte
Beschäftigte von CureVac
-
Jean-Louis Horlait
Owner at JLH Consulting srl
-
Achim Loehr
Vice President Business Development & Licensing at CureVac SE
-
Alexander Zehnder, MD, MBA
Chief Executive Officer @ CureVac
-
Allan Masterson. Ph.D. MBA CPCC ICF
Early Asset Strategy | Commercial Strategy | Policy & Access | Communications | Certified Co Active & ORSC (Team) Coach
Updates
-
🌐 Update on Trial Dates from CureVac! 🌐 CureVac is making strides in the mission to revolutionize medicine with mRNA technology. Today, we announced new trial dates for our ongoing patent litigation against Pfizer/BioNTech in the U.S., alongside related proceedings in Germany and the UK. Read the full Press Release here: https://lnkd.in/dbbmSgvD #CureVac #mRNA #Biopharmaceuticals #Innovation #PatentLitigation #BiotechNews
-
🚀New Licensing Agreement! 🚀 We're excited to announce today that CureVac has entered into a new licensing agreement with our long-time partner, GSK. Under this agreement, GSK will take over and obtain all developing, manufacturing and marketing rights for COVID-19 and flu vaccine candidates, including COVID/flu combinations. In return, CureVac will receive substantial upfront and milestone payments as well as tiered royalties, supporting us to move onto our next chapter and focus on what we do best – pushing the boundaries of what’s possible with mRNA innovation. While we unfortunately had to make the tough decision, also announced today, to trim our workforce as we enter this next era of the company, it will ultimately make CureVac stronger and put us in a better position to continue to innovate in the future and be a lasting force in the mRNA field. Please find the licensing agreement press release here: https://lnkd.in/ecz8Jx49 Please find the restructuring press release here: https://lnkd.in/e6ntMN7E #CureVac #GSK #VaccineDevelopment #Innovation #Healthcare #ResearchAndDevelopment #Biotech #CureVac2.0
-
📢 Our CEO Alexander Zehnder, MD, MBA is featured in the latest issue of Drug Discovery World Summer 2024! 📢 Starting on page 46, he shares insights on the cutting-edge advancements in the field of mRNA and its impact on drug discovery. Don't miss out on this in-depth discussion on how these innovations could potentially shape the future of personalized medicine. Read the full article here: https://lnkd.in/gtSZijU9 #CureVac #DDWSummer2024 #DrugDiscovery #PersonalizedMedicine
DDW Summer 2024 - Drug Discovery World (DDW)
https://www.ddw-online.com
-
We are eager to share insights on the latest advancements in cancer vaccines! Our Chief Scientific Officer, Dr. Myriam Mendila , has contributed her expert opinion on this crucial topic. Check out her thoughts and the broader discussion on how mRNA-based cancer vaccines could potentially activate the immune system in the article of The Medicine Maker. Don't miss this essential read! Read more: https://lnkd.in/eKVD-qY6 #CureVac #CancerResearch #CancerVaccines #Immunotherapy #CSO #MyriamMendila #TheMedicineMaker
Cancer Vaccines: Activate the Immunosoldiers – Part I
themedicinemaker.com
-
🌟 Meet Manuel Göpferich, Bioinformatician-Data Engineer from CureVac, at The European mRNA Conference 2024 in Frankfurt! 🌟 Manuel will be discussing the Design of Optimised UTR Sequences Using Support Vector Machines. This event is a great opportunity to learn from industry experts and provide insights into the innovative work happening at CureVac. Join him and others: https://lnkd.in/eQyVemY9 #CureVac #mRNA #PharmaInnovation #PharmaEvents #Biotechnology #Healthcare
-
Today, we successfully held our Annual General Meeting in the beautiful city of Amsterdam. We reflected on 2023 as a year of remarkable achievements and shared insights into our latest developments. We are also excited to introduce Birgit Hofmann as a new member of the supervisory board. Welcome to CureVac, Birgit! Thank you to all our investors for your trust and support. Also thank you everyone who made this event a success! Together, we are shaping the future of healthcare. #CureVac #AGM #Amsterdam #Biotech #Innovation #Healthcare
-
Celebrating Pride Month at CureVac: Embracing Diversity and Inclusion! 🌈 June is Pride Month, and we at CureVac are proud to support the LGBTQ+ community. Diversity and inclusion are at the core of our company values, and we believe that a diverse and inclusive workplace is essential for innovation and success. Our strength lies in the uniqueness of our RNA people, and we are committed to fostering an environment where everyone can thrive. This Pride Month, we celebrate the vibrant and diverse voices that make CureVac a special place to work. #PrideMonth #DiversityAndInclusion #CureVacCares
-
🌟 Back-to-back excitement awaits as we gear up for the Goldman Sachs 45th Annual Global Healthcare Conference in Miami today! 🌟 Join us for another round of insightful discussions and networking opportunities alongside industry stalwarts and investment enthusiasts. Our team, including our new Chief Business Officer Thaminda Ramanayake, CEO Alexander Zehnder, MD, MBA and Dr. Sarah Fakih, MBA, Vice President Corporate Communications and Investor Relations, will be there to represent CureVac once again.
-
We are delighted to share that we will be participating in the 2024 Annual Congress of the European Association for Cancer Research (EACR), which will take place from June 10-13 in Rotterdam. This prestigious event brings together cancer researchers, clinicians, and industry experts from around the world to share groundbreaking insights. At EACR 2024, we will be showcasing our approaches in oncology, the next frontier for mRNA technology. Our team has been working tirelessly to advance our unique platform in this field, and we’re excited to share our findings with the scientific community. Read more about the event: https://2024.eacr.org/
Ähnliche Seiten
Jobs durchsuchen
Finanzierung
Letzte Runde
Kapitalerhöhung nach Börsengang250.000.000,00 $